Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for prevention of chemotherapy-induced nausea and vomiting in breast cancer
IRCT20251125068107N1Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoint: Nausea and vomiting. Started Dec 2025; status: completed.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20251125068107N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251125068107N1.